Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹58.57 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹58.57 Cr |
| Fresh Issue | ₹45.07 Cr |
| Offer for Sale | ₹10.56 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹91.00-96.00 per share |
| Discount | Retail: 0.00,Employee: 0.00,ShareHolder: 0.00 |
| NSE Code | INFLUX |
| Registrar | Maashitla Securities Pvt.Ltd. |
| Lead Managers | Rarever Financial Advisors Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 1,200 shares and in multiples thereof
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing. The company is a reliable CDMO, providing specialized services to clients in multiple industries.
The company has three manufacturing facilities in Thane, Maharashtra, each covering an area of 9,676 square feet, 13,000 square feet, and 14,000 square feet, respectively.
Product Portfolio:
The Company aids Nutraceutical and Cosmetic firms with product development and manufacturing. It offers end-to-end services, including development, production, and regulatory support, enabling clients to focus on formulation and commercialization.
As of June 11, 2025, the company has 163 permanent employees on a payroll basis.
Competitive Strength
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division | 22.60 |
| 2 | Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division | 11.59 |
| 3 | Purchase of Machineries for Homecare and Cosmetic Division | 2.76 |
| 4 | General Corporate Purposes | 5.44 |
| 5 | Issue Expenses | 5.83 |
| Total | 48.21 |
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 70.30 | 41.10 | 28.30 |
| Total Income | 104.99 | 100.10 | 76.07 |
| Profit After Tax | 13.37 | 11.22 | 7.20 |
| NET Worth | 36.15 | 22.87 | 11.65 |
| Reserves and Surplus | 18.00 | 22.85 | 11.63 |
| Total Borrowing | 0.22 | 0.32 | 0.80 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 36.98% |
| ROCE | 49.17% |
| Debt / Equity | 0.01% |
| RoNW | 36.98% |
| PAT Margin | 12.75% |
| EBITDA Margin | 19.62% |
| Price to Book Value | 4.82 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 7.36 | 5.77 |
| P/E (x) | 13.04 | 16.63 |
| Promoter Holding | 99.85% | 73.53% |
| Market Cap | ₹222.24 Cr. | |
